Amphastar P (AMPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amphastar P (AMPH) has a cash flow conversion efficiency ratio of 0.062x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($47.84 Million) by net assets ($773.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Amphastar P liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Amphastar P - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Amphastar P's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amphastar P Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amphastar P ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aeva Technologies, Inc. Common Stock
NASDAQ:AEVA
|
2.083x |
|
Tigerair Taiwan Co. Ltd.
TW:6757
|
0.292x |
|
Yatharth Hospital & Trauma Care Services Limited
NSE:YATHARTH
|
0.027x |
|
China Building Material
SHG:603060
|
0.043x |
|
ALPHAMAB ONCOLO.DL-000002
F:3NK
|
N/A |
|
Theravance Biopharma Inc
NASDAQ:TBPH
|
-0.020x |
|
Yeo Teknoloji Enerji ve Endustri AS
IS:YEOTK
|
-0.363x |
|
Indus Holding AG
XETRA:INH
|
0.096x |
Annual Cash Flow Conversion Efficiency for Amphastar P (2012–2025)
The table below shows the annual cash flow conversion efficiency of Amphastar P from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see AMPH stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $788.80 Million | $156.12 Million | 0.198x | -32.08% |
| 2024-12-31 | $732.30 Million | $213.39 Million | 0.291x | +1.54% |
| 2023-12-31 | $639.42 Million | $183.50 Million | 0.287x | +70.12% |
| 2022-12-31 | $528.66 Million | $89.18 Million | 0.169x | -23.30% |
| 2021-12-31 | $445.52 Million | $97.99 Million | 0.220x | +72.35% |
| 2020-12-31 | $448.72 Million | $57.27 Million | 0.128x | +30.65% |
| 2019-12-31 | $427.53 Million | $41.76 Million | 0.098x | -6.81% |
| 2018-12-31 | $364.36 Million | $38.19 Million | 0.105x | -9.82% |
| 2017-12-31 | $337.33 Million | $39.21 Million | 0.116x | -0.75% |
| 2016-12-31 | $329.25 Million | $38.56 Million | 0.117x | +224.01% |
| 2015-12-31 | $295.51 Million | $10.68 Million | 0.036x | -51.61% |
| 2014-12-31 | $281.86 Million | $21.05 Million | 0.075x | -39.48% |
| 2013-12-31 | $251.54 Million | $31.04 Million | 0.123x | +1845.92% |
| 2012-12-31 | $233.44 Million | $-1.65 Million | -0.007x | -- |
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more